Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Molecules (Basel, Switzerland)
|
December 20, 2017
Vanadium Compounds as PTP Inhibitors
Elsa Irving, Andrew W Stoker
Trends in Molecular Medicine
|
September 28, 2020
The Ubiquitin/UBL Drug Target Repertoire
Hugh C Osborne, Elsa Irving, Christine K Schmidt
Cancers
|
January 11, 2022
Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
Rosario Prados-Carvajal, Elsa Irving, Natalia Lukashchuk, et al.
Trends in Cell Biology
|
March 9, 2021
E2 enzymes in genome stability: pulling the strings behind the scenes
Hugh C Osborne, Elsa Irving, Josep V Forment, et al.
Scientific Reports
|
October 8, 2020
The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells
Elsa Irving, Aristides D Tagalakis, Ruhina Maeshima, et al.
Journal of Drug Targeting
|
January 7, 2020
Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells
Maja Bilip, Shreya Shah, Mayuran Mathiyalakan, et al.
Cancers
|
January 28, 2026
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance
Elsa Irving, Alaide Morcavallo, Jekaterina Vohhodina-Tretjakova, et al.
Journal of Medicinal Chemistry
|
June 16, 2026
Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers
Sharan K Bagal, Coura R N Diène, Sandra Stefanovic-Barrett, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Molecules (Basel, Switzerland)
|
December 20, 2017
Vanadium Compounds as PTP Inhibitors
Elsa Irving, Andrew W Stoker
Trends in Molecular Medicine
|
September 28, 2020
The Ubiquitin/UBL Drug Target Repertoire
Hugh C Osborne, Elsa Irving, Christine K Schmidt
Cancers
|
January 11, 2022
Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
Rosario Prados-Carvajal, Elsa Irving, Natalia Lukashchuk, et al.
Trends in Cell Biology
|
March 9, 2021
E2 enzymes in genome stability: pulling the strings behind the scenes
Hugh C Osborne, Elsa Irving, Josep V Forment, et al.
Scientific Reports
|
October 8, 2020
The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells
Elsa Irving, Aristides D Tagalakis, Ruhina Maeshima, et al.
Journal of Drug Targeting
|
January 7, 2020
Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells
Maja Bilip, Shreya Shah, Mayuran Mathiyalakan, et al.
Cancers
|
January 28, 2026
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance
Elsa Irving, Alaide Morcavallo, Jekaterina Vohhodina-Tretjakova, et al.
Journal of Medicinal Chemistry
|
June 16, 2026
Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers
Sharan K Bagal, Coura R N Diène, Sandra Stefanovic-Barrett, et al.
Page
of 1